2EV-24563-58020
3 vaccinations
1 coded response
15 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 601 / IL
- Registered
- 2021-12-31
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-29
Dose 1 — Moderna
-
2021-03-05
Dose 2 — Moderna
-
2021-12-30
Dose 3 — Moderna
-
2021-12-31
Registered in v-safe
-
2021-12-31
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Fatigue or tirednessAdult check-in
-
2022-01-01
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2022-01-02
- 2022-01-03
- 2022-01-04
- 2022-01-05
- 2022-01-06
- 2022-01-13
- 2022-01-20
- 2022-01-27
- 2022-02-03
- 2022-02-10
- 2022-03-31
-
2022-06-30
Survey response — 6 months, dose 3MedDRA: Malaise, Nasopharyngitis, SARS-CoV-2 test negative — Feeling: GoodFree text: Ill with cold symptoms but negative COVID tests. Resolved and feeling better.MedDRA releases: 2024-11 · check-in free text available
- 2022-12-30
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-29 | Moderna | No |
| 2 | 2021-03-05 | Moderna | No |
| 3 | 2021-12-30 | Moderna | No |
Free text
Release 12 — 6 months, dose 3
Symptoms: Ill with cold symptoms but negative COVID tests. Resolved and feeling better.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Malaise | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | SARS-CoV-2 test negative | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release